Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects

Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects
Jon Eckard, PhD, TYME Inc., shares Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects at Annual Meeting 2018.
111 Views
5 years Ago
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Sarcoma

Advanced Angiosarcoma Care: Cabozantinib Plus Nivolumab Promise
Advanced Angiosarcoma Care: Cabozantinib Plus Nivolumab Promise
126 Views
Oncology Conferences
Exploring Cabozantinib Plus Nivolumab: A Breakthrough in Advanced Angiosarcoma - An Interview with Dr. Gary Schwartz
Exploring Cabozantinib Plus Nivolumab: A Breakthrough in Advanced Angiosarcoma - An Interview with Dr. Gary Schwartz
499 Views
Oncology Conferences
ASCO [2022] Sarcomas Cancer In-Depth Slides: MOASC
ASCO [2022] Sarcomas Cancer In-Depth Slides: MOASC
185 Views
MOASC
Podcast - Kilian E. Salerno, MD @theNCI @ASTRO_org #RadiationTherapy #SoftTissueSarcoma #Cancer #Research ASTRO Issues Clinical Guideline On Radiation Therapy For Soft Tissue Sarcoma In A...
Podcast - Kilian E. Salerno, MD @theNCI @ASTRO_org #RadiationTherapy #SoftTissueSarcoma #Cancer #Research ASTRO Issue...
30 Views
Cancer News
Kilian E. Salerno, MD @theNCI @ASTRO_org #RadiationTherapy #SoftTissueSarcoma #Cancer #Research ASTRO Issues Clinical Guideline On Radiation Therapy For Soft Tissue Sarcoma In Adults
Kilian E. Salerno, MD @theNCI @ASTRO_org #RadiationTherapy #SoftTissueSarcoma #Cancer #Research ASTRO Issues Clinical...
84 Views
Cancer News
Erik A. Williams, MD @FoundationATCG #softtissuesarcoma CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1
Erik A. Williams, MD @FoundationATCG #softtissuesarcoma CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Cla...
132 Views
Annual Meeting
Hoping T-cell Therapies Will Lead to Approval Difficult to treat solid tumors with adoptive T-cell
Hoping T-cell Therapies Will Lead to Approval Difficult to treat solid tumors with adoptive T-cell
176 Views
Annual Meeting
Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects
Trial Designed to Target Unique Tumor Biology Most cancer therapies come with side-effects
111 Views
Annual Meeting
MRCLS Responded to Active Therapy Treatment Harvested T-Cells transduced with antiviral vector
MRCLS Responded to Active Therapy Treatment Harvested T-Cells transduced with antiviral vector
171 Views
Annual Meeting
Infusion of T-Lymphocytes with T-Cell Receptor MRCLS could be sensitive to therapy
Infusion of T-Lymphocytes with T-Cell Receptor MRCLS could be sensitive to therapy
120 Views
Annual Meeting
Myxoid Round Cell Liposarcoma Expresses NY-ESO-1 T-Cell therapy targeting NY-ESO-1 can induce response
Myxoid Round Cell Liposarcoma Expresses NY-ESO-1 T-Cell therapy targeting NY-ESO-1 can induce response
123 Views
Annual Meeting
Created a number of followup studies Testing checkpoint Inhibitors, PD-1 blockade
Created a number of followup studies Testing checkpoint Inhibitors, PD-1 blockade
112 Views
Annual Meeting